Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2007

View Archived Issues

Novel animation depicting GLP-1 and DPP IV as therapeutic targets for diabetes and obesity

STRIDE preliminary results reveal safety and activity of I-vation Triamcinolone Intravitreal Implant

Common pathogenic mechanisms in AD and ocular degenerative diseases

Recent patents disclose new anxiolytic and antipsychotic agents

Therapeutic agents for allergic and respiratory disorders described in recent patents

Promising neuroprotective and antioxidant effects of AEOL-11207 in an MPTP model of Parkinsonism

Recent patents impart novel treatment options for autoimmune and inflammatory disorders

Accentia reaches milestone in SinuNase development; CRSFungal Profile commercialized

Commercialization agreement signed for NeuroBloc

ODAC to review satraplatin in July

Paramount BioSciences obtains license to SonoLight technology for dermatology indications

Boehringer Ingelheim announces measure to expand reach of HIV therapy

Patient enrollment begins in Aridol trial for COPD

Interim analysis of talabostat phase III NSCLC clinical trial to be conducted

SIGA's Lassa fever drug candidate shows promise in animal models

Indaflex shows potential in phase II for osteoarthritis

Testosterone improves cognitive performance in multiple sclerosis

Promising phase IIa study results reported for house dust mite allergy product candidate

Oxycyte reaches primary endpoint in TBI phase IIa trial

Luitpold seeks FDA approval for iron replacement therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...